Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third-quarter 2025 dividend of $0.43 per share. Alongside these developments, ...

Pfizer Inc. (NYSE:PFE) is one of the Best Dividend Leaders to Buy Now. The company’s strategy focuses on steadily increasing ...

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Pfizer (NYSE:PFE) stock is a biopharmaceutical firm that had a magnificent breakout in 2021 as the worst of the pandemic sent ...

Income investors have liked Pfizer (NYSE: PFE) for years. However, the big drugmaker's exceptionally juicy dividend these days has made its stock even more attractive. But when a dividend yield ...

Is Pfizer's high dividend worth the risk? Let's dig deeper to find out. A pharmaceutical powerhouse facing challenges. Pfizer is a global pharmaceutical giant with an impressive portfolio of over ...

Dividend stocks can set you up for life. But, making the right choice will determine whether you enjoy a steady income or ...

The good news on this front, though, is that Pfizer is poised to improve its bottom line and make its dividend even safer. Sure, the big pharma company's earnings fell 11% year over year in Q2.

That said, Pfizer Inc. (NYSE:PFE) has a five-year average payout ratio above 101%, which may seem alarming at first. A company can’t consistently pay more in dividends than it earns.